- Home
- OPT vs INNV Comparison
OPT vs INNV Comparison
Compare OPT & INNV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPT
- INNV
- Stock Information
- Founded
- OPT 1984
- INNV 2007
- Country
- OPT Australia
- INNV United States
- Employees
- OPT N/A
- INNV N/A
- Industry
- OPT Biotechnology: Biological Products (No Diagnostic Substances)
- INNV Medical/Nursing Services
- Sector
- OPT Health Care
- INNV Health Care
- Exchange
- OPT Nasdaq
- INNV Nasdaq
- Market Cap
- OPT 767.9M
- INNV 817.8M
- IPO Year
- OPT 2020
- INNV 2021
- Fundamental
- Price
- OPT $3.24
- INNV $5.26
- Analyst Decision
- OPT Strong Buy
- INNV Hold
- Analyst Count
- OPT 1
- INNV 3
- Target Price
- OPT $12.00
- INNV $6.50
- AVG Volume (30 Days)
- OPT 39.0K
- INNV 30.0K
- Earning Date
- OPT 08-30-2024
- INNV 11-05-2024
- Dividend Yield
- OPT N/A
- INNV N/A
- EPS Growth
- OPT N/A
- INNV N/A
- EPS
- OPT N/A
- INNV N/A
- Revenue
- OPT $261,859.00
- INNV $786,512,000.00
- Revenue This Year
- OPT N/A
- INNV $13.17
- Revenue Next Year
- OPT $46,864.64
- INNV $10.46
- P/E Ratio
- OPT N/A
- INNV N/A
- Revenue Growth
- OPT N/A
- INNV 12.46
- 52 Week Low
- OPT $1.79
- INNV $3.52
- 52 Week High
- OPT $5.45
- INNV $6.69
- Technical
- Relative Strength Index (RSI)
- OPT 27.29
- INNV 34.75
- Support Level
- OPT $4.02
- INNV $5.80
- Resistance Level
- OPT $4.18
- INNV $5.94
- Average True Range (ATR)
- OPT 0.22
- INNV 0.35
- MACD
- OPT -0.13
- INNV -0.08
- Stochastic Oscillator
- OPT 6.85
- INNV 6.54
About OPT Opthea Limited
Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. The company geographically operates Australia and United States.
About INNV InnovAge Holding Corp.
InnovAge Holding Corp is a healthcare delivery platform by several participants focused on providing all-inclusive, capitated care to high-cost, dual-eligible seniors. Its patient-centered care delivery approach improves the quality of care while keeping them in their homes and reducing over-utilization of high-cost care settings such as hospitals and nursing homes. The company's segment includes PACE and others. It generates maximum revenue from the PACE segment.